<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158492</url>
  </required_header>
  <id_info>
    <org_study_id>HUB-INF-RADICAP</org_study_id>
    <nct_id>NCT04158492</nct_id>
  </id_info>
  <brief_title>Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia</brief_title>
  <acronym>RADICAP</acronym>
  <official_title>Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia: an Open, Controlled and Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health, Generalitat de Catalunya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Community-acquired pneumonia (CAP) continues to be a major health problem with
      significant mortality and it's one of the main causes of antibiotic prescription. Antibiotic
      overuse is a key driver of antimicrobial resistance and exposes patients to an increased risk
      of other antibiotic-related adverse events. The investigators aim to assess if rapid
      molecular tests are an effective tool to reduce antibiotic use in CAP compared to routine
      microbiological testing.

      Design: Randomized, controlled, open-label clinical trial with two parallel groups (1:1)
      settled in a two-year multicenter, two tertiary care hospitals, between 2019 and 2021.
      Eligible participants will be non-severely immunosuppressed adult patients hospitalized for
      CAP through the emergency department. Primary endpoint will be antibiotic consumption
      measured by days of antibiotic therapy (DOT) per 1000 patient-days. Secondary end points will
      be: de-escalation to narrower antibiotic treatment, time to switch from intravenous to oral
      antibiotics, antibiotic-related side effects, length of hospital stay, days until clinical
      stability, need for ICU admission, need for hospital readmission in the 30 days after
      randomization, death from any cause in the 30 days after randomization. Patients will be
      randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to
      routine microbiological testing) or standard diagnosis (only microbiological routine
      testing). A total of 220 patients are estimated in the experimental arm (undergoing
      comprehensive molecular testing) and 220 control subjects (undergoing routine testing) to be
      able to reject the null hypothesis that experimental and control groups have equal DOT per
      1000 patients-days with a probability above 0.8.

      Discussion: Comprehensive molecular tests could be a key tool in the optimization of
      etiological diagnostics in CAP and, therefore, a key element in antimicrobial stewardship
      programs developed to improve safety and antibiotic use in CAP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled, open-label clinical trial with two parallel groups (1:1) settled in two tertiary care hospitals</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of DOT/1000 patients</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of days of antibiotic therapy per 1000 patient-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days with intravenous antibiotic treatment.</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of days of intravenous antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until de-escalation</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of days until de-escalation of antibiotic treatment to another of narrower spectrum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until antimicrobial monotherapy</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of days untilt antimicrobial monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days until etiological diagnosis</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of days until detection of the causal agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of Oxygen treatment</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Days of oxygen treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of non-invasive ventilation</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Days of invasive or non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospital admission</measure>
    <time_frame>Up to hospital discharge - a medium of 5 days</time_frame>
    <description>Number of days of hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of readmissions</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Rate of patients who are readmitted after hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complicated community-acquired pneumonia (CAP)</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Rate of complications related to CAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of general complications</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Patients with medical complications not directly related to CAP until the end of the clinical trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of total adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events related to antimicrobials</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of adverse events related to antibiotic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clostridium difficile infection</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of patients diagnosed with Clostridium difficile infection during the clinical trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phlebitis rate</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of patients with phlebitis resulting from the use of intravenous drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early mortality rate</measure>
    <time_frame>Up tp 5 days after randomization</time_frame>
    <description>Number of patients deceased 5 days after the randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day case-fatality rate</measure>
    <time_frame>Up to 30±5 days after randomization</time_frame>
    <description>Number of patients deceased 30±5 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAP-related fatality rate</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of patients Deceased patients, related to CAP during the clinical trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause fatality rate</measure>
    <time_frame>Up to 30±5 days after hospital discharge</time_frame>
    <description>Number of patients who died from any cause during the clinical trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Standard diagnostic tests</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will undergo only the standard diagnostic procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental + standard diagnostic tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>real-time multiplex PCR</intervention_name>
    <description>Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures</description>
    <arm_group_label>Experimental + standard diagnostic tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard diagnostic procedures</intervention_name>
    <description>Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.</description>
    <arm_group_label>Standard diagnostic tests</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 years of age or older), of both sexes, hospitalized with a
             diagnosis of CAP in the first 24 hours of the admission.

          -  Patient or his legal representative gives the informed consent

        Exclusion Criteria:

          -  Pregnancy and / or nursing.

          -  Severe immunocompromised patients (chemotherapy or radiotherapy in the previous 90
             days, use of immunosuppressive drugs, chronic use of corticosteroids at a minimum dose
             of 15 mg / day in the last two weeks, transplantation of hematopoietic progenitors,
             solid organ transplant, patients with HIV and CD4 count ≤ 200 cells / mm3).

          -  Imminent death (life expectancy ≤ 24 hours).

          -  Participation in another clinical trial of pharmacological treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Carratalà Fernández, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut d'Investigació Biomèdica de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Carratalà Fernández, PhD</last_name>
    <phone>932607500</phone>
    <phone_ext>5778</phone_ext>
    <email>jordicarratala@bellvitgehospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriela Abelenda Alonso, PhD</last_name>
    <phone>932607500</phone>
    <phone_ext>2075</phone_ext>
    <email>gabi.abelenda.alonso@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SCIAS Hospital de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Meije, PhD</last_name>
      <phone>0034932542400</phone>
      <email>ymeije@scias.com</email>
    </contact>
    <investigator>
      <last_name>Yolanda Meije, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucía Ortega, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Clemente, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Abelenda Alonso, MD</last_name>
      <phone>0034932602487</phone>
      <email>gabi.abelenda.alonso@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordi Caratalà, PhD, Prof</last_name>
      <phone>0034932602487</phone>
    </contact_backup>
    <investigator>
      <last_name>Jordi Carratalà, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriela Abelenda-Alonso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Rombauts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlota Gudiol, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Ardanuy, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Niubó, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariadna Padullés, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastián Videla, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Tebé, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Jordi Carratala</investigator_full_name>
    <investigator_title>Head of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>antimicrobial stewardship</keyword>
  <keyword>point-of-care test</keyword>
  <keyword>comprehensive molecular tests</keyword>
  <keyword>multiple PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be made available after evaluating individual request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

